Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0230
NEWS & VIEWS
|
Neoadjuvant treatment and laparoscopic rectal cancer: Precision genomic medicine essential for improving patient's outcomes. |
|
Affiliation: Seung Hyuk Baik, MD. Division of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-749, Korea.
Tel: +82-2-2228-2100, Fax: +82-2-314-8289,
E-mail: whitenoja@yuhs.ac |
Since there is no abstract available we provide the first paragraph.
Preoperative chemotherapy in selected patients with resectable cancer followed by laparoscopic surgery has become popular in the treatment of low and mid rectal cancer. However, recent reviews and meta-analyses suggest limitations of neoadjuvant treatment based on conventional selection (T3,4 and/or N1,2 tumors). Despite enthusiastic reports for accurate neoadjuvant treatment prediction using microarrays-based gene expression signatures, no such arrays-based predictor has been identified for routine clinical use. Here I discuss the question of safety of laparoscopic rectal cancer resection after neoadjuvant treatment. Moreover, the promise and challenges in discovery of novel biomarkers for rectal cancer based on genome sequencing, mapping and functioning using next-generation sequencing technologies are also reported.
(Citation: Gastric & Breast Cancer 2012; 11(3): 143-145)
Rolex Yacht-Master Replica
http://www.gastricbreastcancer.com/gtade_seamaster_1200m.asp
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
|
